Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: Implications for targeted therapy

Pancreas

Volumn 43, Issue 7, 2014, Pages 996-1002

  Estrella, Jeannelyn S ^a   Ma, Ly T ^a   Milton, Denái R ^a   Yao, James C ^a   Wang, Huamin ^a   Rashid, Asif ^a   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ER ; Estrogen induced genes; Pancreatic neuroendocrine tumor

Indexed keywords

ATM PROTEIN; ATR PROTEIN, HUMAN; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; MESSENGER RNA; ONCOPROTEIN; PROGESTERONE RECEPTOR; RNA; SFRP4 PROTEIN, HUMAN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHYSIOLOGY; TUMOR VOLUME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, NEOPLASM; TUMOR BURDEN; YOUNG ADULT;

EID: 84914094546     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000203     Document Type: Article

References (44)

1. Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-1773.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
3. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007;205:558-563.
4. Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013;18:525-532.
5. Klimstra DS, Arnold R, Capella C, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010:322-326.
6. Smith J, Reidy-Lagunes D. The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Semin Oncol. 2013;40:100-108.
7. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173-184.
8. Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer. 2003;10:427-436.
9. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013; 42:557-577.
10. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987;59:1803-1809.
11. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7(suppl 6): S1-S21; quiz S22-S23.
12. Arnason T, Sapp HL, Barnes PJ, et al. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology. 2011;93:249-258.
13. Deng L, Shipley GL, Loose-Mitchell DS, et al. Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. J Clin Endocrinol Metab. 2003;88:2157-2163.
14. Westin SN, Broaddus RR, Deng L, et al. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther. 2009;8:2126-2135.
15. Deng L, Broaddus RR, McCampbell A, et al. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res. 2005;11:8258-8264.
16. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997;81:228-232.
17. Viale G, Doglioni C, Gambacorta M, et al. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992;70: 2268-2277.
18. Alabraba EB, Taniere P, Reynolds GM, et al. Expression and functional consequences of oestrogen and progesterone receptors in human insulinomas. Endocr Relat Cancer. 2007;14:1081-1088.
19. Nieuwenhuizen AG, Schuiling GA, Hilbrands LG, et al. Proliferation of pancreatic islet-cells in cyclic and pregnant rats after treatment with progesterone. Horm Metab Res. 1998;30:649-655.
20. Magnaterra R, Porzio O, Piemonte F, et al. The effects of pregnancy steroids on adaptation of beta cells to pregnancy involve the pancreatic glucose sensor glucokinase. J Endocrinol. 1997;155:247-253.
21. Shao J, Qiao L, Friedman JE. Prolactin, progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 beta-cells. Am J Physiol Endocrinol Metab. 2004;286: E304-E310.
22. Picard F, Wanatabe M, Schoonjans K, et al. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc Natl Acad Sci U S A. 2002;99:15644-15648.
23. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27:1124-1134.
24. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:241-246.
25. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29:e458.
26. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
27. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003;63:2434-2439.
28. Gosden JR, Middleton PG, Rout D. Localization of the human oestrogen receptor gene to chromosome 6q24-q27 by in situ hybridization. Cytogenet Cell Genet. 1986;43:218-220.
29. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258-4265.
30. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem. 1998;273:12101-12108.
31. Bardin A, Hoffmann P, Boulle N, et al. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res. 2004;64:5861-5869.
32. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997;11:353-365.
33. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol. 2004;50:3-22.
34. Gallo D, De Stefano I, Grazia Prisco M, et al. Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des. 2012;18: 2734-2757.
35. Soriano S, Ropero AB, Alonso-Magdalena P, et al. Rapid regulation of K (ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor. Mol Endocrinol. 2009;23:1973-1982.
36. Alonso-Magdalena P, Ropero AB, Garcia-Arevalo M, et al. Antidiabetic actions of an estrogen receptor beta selective agonist. Diabetes. 2013;62: 2015-2025.
37. Bossard C, Busson M, Vindrieux D, et al. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One. 2012;7:e44787.
38. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004;64:423-428.
39. Jarvinen TA, Pelto-Huikko M, Holli K, et al. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156:29-35.
40. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004;57:523-528.
41. Estrella J, Broaddus R, Mathews A, et al. Progesterone receptor and PTEN expression predict survival in patients with low and intermediate grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2013.
42. Deng L, Feng J, Broaddus RR. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis. 2010;1:e32.
43. Kapp AV, Jeffrey SS, Langerod A, et al. Discovery and validation of breast cancer subtypes. BMC Genomics. 2006;7:231.
44. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res. 2006;12:3661-3697.